Project Oncology®

Dr. Osita Onugha, thoracic surgeon at the Providence Specialty Medical Group in Santa Monica, California discusses how prognostic markers can be used to help guide non-small cell lung cancer treatment decisions.

Dr. Chandrajit P. Raut, Chief of the Division of Oncology at Brigham and Women’s Hospital, gives us a sneak preview of his presentation on the surgical management of breast angiosarcoma at the upcoming 2021 American Society of Clinical Oncology Annual Meeting.

In anticipation of the upcoming American Society of Clinical Oncology Annual Meeting, Dr. Kevin Kalinsky shares clinical trials and presentations that he’s looking forward to seeing.

Dr. Charles Turck explores first-line treatment for metastatic EGFR mutated non-small cell lung cancer with pneumonologist Dr. Nicolas Girard, the head of medical oncology at the Institut Curie in Paris.

Here to give us a brief overview of her session at the 2021 American Society of Clinical Oncology Annual Meeting titled, “From Desmoid and Phyllodes to UPS: A One-Size-Does-Not-Fit-All Approach to Surgery,” is Dr. Kelly Hunt, Professor and Chair of the Department of Breast Surgical Oncology in the Division of Surgery at the University of Texas MD Anderson Cancer Center.

Here to give us a brief overview of her session at the 2021 American Society of Clinical Oncology Annual Meeting titled, “From Desmoid and Phyllodes to UPS: A One-Size-Does-Not-Fit-All Approach to Surgery,” is Dr. Kelly Hunt, Professor and Chair of the Department of Breast Surgical Oncology in the Division of Surgery at the University of Texas MD Anderson Cancer Center.

Dr. Charles Turck sits down with Dr. Christine Bestvina, Assistant Professor of Medicine in the Section of Hematology and Oncology at University of Chicago Medicine, to discuss best practices and adverse events when it comes to treating non-small cell lung cancer.

Immunotherapy has led to impressive results, but when is it needed? Dr. Jacob Sands discusses the role of immunotherapy in managing lung cancer with Dr. Mark Awad, a thoracic medical oncologist, Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School.­

What do we need to know about the role of biomarkers in non-small cell lung cancer? Dr. Mark Awad from the Dana-Farber Cancer Institute explains.

Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.